UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 29, 2013
Supernus Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
(State or other jurisdiction of Incorporation) |
|
0-50440 |
|
20-2590184 |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
|
|
|
|
1550 East Gude Drive, Rockville MD |
|
20850 |
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (301) 838-2500
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
_________________________________________________________________________________________
Item 8.01 Other Events
On August 29, 2013, Supernus issued a press release announcing that the Company’s management will be presenting an overview of the Company at investor conferences on September 9, 2013 and September 12, 2013. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
On September 5, 2013, Supernus issued a press release announcing that Trokendi XR™ is now available to patients in the United States. Trokendi XR is a novel once-daily extended release formulation of topiramate for the treatment of epilepsy. The product has been shipped to major wholesalers in the market, and the Company’s sales force is promoting the product to physicians. A copy of this press release is furnished as Exhibit 99.2 hereto and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following documents are furnished as Exhibits pursuant to Item 8.01 hereof:
Exhibit 99.1 – Press Release dated August 29, 2013 of the Company announcing that the Company’s management will be presenting at two investor conferences in September 2013.
Exhibit 99.2 – Press Release dated September 5, 2013 of the Company announcing the commercial launch of Trokendi XR in the United States.
_________________________________________________________________________________________
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SUPERNUS PHARMACEUTICALS, INC.
|
DATED: September 5, 2013 |
By: /s/ Gregory S. Patrick |
|
|
Gregory S. Patrick |
|
|
Vice-President and Chief Financial Officer |
|
|
|
EXHIBIT INDEX
|
|
|
|
|
Number |
Description |
|
|
|
|
|
|
|
|
|
|
99.1 |
Press Release dated August 29, 2013. |
Attached |
|
|
||
|
99.2 |
Press Release dated September 5, 2013. |
Attached |
|
|
||
EXHIBIT 99.1
FOR IMMEDIATE RELEASE
Supernus to Present at Two Investor Conferences in September
Rockville, MD, August 29, 2013 -Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company, today announced that the Company’s management will present an overview of the Company at the following investor conferences in September 2013:
Rodman & Renshaw:
Presentation Date: Monday, September 9
Time: 11:40am ET
Place: Millennium Broadway Hotel, NY
Stifel Nicolaus Weisel:
Presentation Date: Thursday, September 12
Time: 1:30pm ET
Place: Four Seasons Hotel, Boston, MA
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The Company has one marketed product for epilepsy, Oxtellar XR™ (extended-release oxcarbazepine), and one approved product for epilepsy, Trokendi XR™ (extended-release topiramate). The Company is also developing several product candidates in psychiatry to address large market opportunities in ADHD, including ADHD patients with impulsive aggression. These product candidates include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.
CONTACTS:
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
EXHIBIT 99.2
FOR IMMEDIATE RELEASE
Supernus Launches Trokendi XR™ in the United States
Rockville, MD, September 5, 2013 --Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company, today announced that Trokendi XR™ is now available to patients in the United States. Trokendi XR is a novel once-daily extended release formulation of topiramate for the treatment of epilepsy. The product has been shipped to major wholesalers in the market, and the Company’s sales force is promoting the product to physicians.
“We have built our sales force from the ground up, and this is our second product launch this year, representing a remarkable achievement for Supernus. Supernus is now a major player in epilepsy, offering two novel and differentiated products to patients. The Company continues its long standing heritage of excellence in execution against its corporate goals. I would like to take this opportunity to thank all Supernus employees for their hard work and dedication that allowed us to launch Trokendi XR very shortly after receiving FDA approval,” said Jack Khattar, President & CEO, of Supernus.
About Trokendi XR™
Trokendi XR is a novel once-daily extended release formulation of topiramate. Trokendi XR is an antiepileptic drug indicated for initial monotherapy in patients 10 years of age and older with partial onset or primary generalized tonic-clonic seizures; adjunctive therapy in patients 6 years of age and older with partial onset or primary generalized tonic-clonic seizures; and adjunctive therapy in patients 6 years of age and older with seizures associated with Lennox-Gastaut syndrome. The product is available in 25mg, 50mg, 100mg and 200mg extended-release capsules.
For full prescribing and safety information, click here.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The Company has two marketed products for epilepsy, Oxtellar XR™ (extended-release oxcarbazepine) and Trokendi XR™ (extended-release topiramate). The Company is also developing several product candidates in psychiatry to address large market opportunities in ADHD, including ADHD patients with impulsive aggression. These product candidates include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.
Forward Looking Statements
This press release contains forward-looking statements regarding the potential for Trokendi XR to treat epilepsy and the timing of the product's availability to physicians. Actual results may differ materially from those in these forward-looking statements as a result of various factors, including, but not limited to, risks regarding the company's ability to commercialize the product successfully, whether physicians will prescribe and patients will use the product, once available, and competition in the market. For a further description of these and other risks facing the Company, please see the risk factors described in the Company's Annual Report Form on 10-K that was filed with the United States Securities and Exchange Commission on March 15, 2013 and under the caption "Risk Factors" and the updates to these
risk factors in the Company's quarterly report on Form 10-Q that was filed with the Commission on August 14, 2013. Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise these statements, except as may be required by law.
CONTACTS:
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591